Trial · NCT03400033
Results by group162
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 162
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change From Baseline in Hemoglobin Levels Over the Evaluation Period (Week 28 to Week 52) | Daprodustat | -0.04 | Standard Error 0.045 | Grams per deciliter (g/dL) | |
| Mean Change From Baseline in Hemoglobin Levels Over the Evaluation Period (Week 28 to Week 52) | Epoetin Alfa | 0.02 | Standard Error 0.066 | Grams per deciliter (g/dL) | |
| Mean Average Monthly On-treatment Intravenous (IV) Iron Dose Per Participant | Daprodustat | 98.11 | Standard Error 11.049 | Milligrams | |
| Mean Average Monthly On-treatment Intravenous (IV) Iron Dose Per Participant | Epoetin Alfa | 106.23 | Standard Error 15.569 | Milligrams | |
| Change From Baseline in Hemoglobin Levels at Week 52 | Daprodustat | -0.03 | Standard Error 0.069 | Grams per deciliter | |
| Change From Baseline in Hemoglobin Levels at Week 52 | Epoetin Alfa | 0.11 | Standard Error 0.098 | Grams per deciliter | |
| Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) Over Evaluation Period (Week 28 to Week 52) | Daprodustat | 70.83 | Inter-Quartile Range 50.98 to 91.07 | Percentage of days | |
| Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) Over Evaluation Period (Week 28 to Week 52) | Epoetin Alfa | 61.76 | Inter-Quartile Range 29.69 to 85.19 | Percentage of days | |
| Number of Hemoglobin Responders in the Hemoglobin Analysis Range (10 to 11.5 Grams/Deciliter) Over Evaluation Period (Week 28 to Week 52) | Daprodustat | 172 | Participants | ||
| Number of Hemoglobin Responders in the Hemoglobin Analysis Range (10 to 11.5 Grams/Deciliter) Over Evaluation Period (Week 28 to Week 52) | Epoetin Alfa | 68 | Participants | ||
| Percentage of Participants Permanently Stopping Study Treatment Due to Meeting Rescue Criteria | Daprodustat | 2.2 | Percentage of participants | ||
| Percentage of Participants Permanently Stopping Study Treatment Due to Meeting Rescue Criteria | Epoetin Alfa | 2.2 | Percentage of participants | ||
| Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Pressure (MAP) at Week 52 | Daprodustat | SBP | -3.18 | Standard Error 1.470 | Millimeter of mercury (mmHg) |
| Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Pressure (MAP) at Week 52 | Epoetin Alfa | SBP | 0.55 | Standard Error 2.252 | Millimeter of mercury (mmHg) |
| Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Pressure (MAP) at Week 52 | Daprodustat | DBP | -2.52 | Standard Error 0.764 | Millimeter of mercury (mmHg) |
| Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Pressure (MAP) at Week 52 | Epoetin Alfa | DBP | -0.29 | Standard Error 1.176 | Millimeter of mercury (mmHg) |
| Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Pressure (MAP) at Week 52 | Daprodustat | MAP | -2.72 | Standard Error 0.907 | Millimeter of mercury (mmHg) |
| Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Pressure (MAP) at Week 52 | Epoetin Alfa | MAP | -0.12 | Standard Error 1.389 | Millimeter of mercury (mmHg) |
| Change From Baseline in SBP, DBP and MAP at End of Treatment | Daprodustat | SBP | -1.4 | Standard Error 1.24 | Millimeter of mercury (mmHg) |
| Change From Baseline in SBP, DBP and MAP at End of Treatment | Epoetin Alfa | SBP | -0.9 | Standard Error 1.75 | Millimeter of mercury (mmHg) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03400033/results